Biological
GM-CSF (sargramostim)
GM-CSF (sargramostim) is a biological therapy with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
1(17%)
Results Posted
80%(4 trials)
Phase Distribution
Ph phase_2
5
83%
Ph phase_1
1
17%
Phase Distribution
1
Early Stage
5
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
5(83.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(5)
Detailed Status
Completed5
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (16.7%)
Phase 25 (83.3%)
Trials by Status
completed583%
recruiting117%
Recent Activity
1 active trials
Showing 5 of 6
recruitingphase_1
Tebentafusp-tebn With LDT in Metastatic UM
NCT06626516
completedphase_2
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
NCT00488592
completedphase_2
Vaccine Therapy in Treating Patients With Breast Cancer
NCT00524277
completedphase_2
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
NCT00940342
completedphase_2
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
NCT00157573
Clinical Trials (6)
Showing 6 of 6 trials
NCT06626516Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
NCT00488592Phase 2
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
NCT00524277Phase 2
Vaccine Therapy in Treating Patients With Breast Cancer
NCT00940342Phase 2
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
NCT00157573Phase 2
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
NCT00501644Phase 2
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6